Fig. 1: PP-007 is a strong inducer of HO-1 in macrophages.

a Schematic cartoon showing the treatment regimen. b, c Representative western blot (WB) and densitometric analysis of HO-1 in WT MΦs treated with 2 mg/ml or 4 mg/ml PP-007 for the time indicated. d qPCR of Hmox-1 in WT MΦs treated with 2 mg/ml PP-007 for the time indicated. e Cartoon showing the experimental design: WT BMD-MΦs were pretreated with 2 mg/ml PP-007 for 6 h and then challenged with PA-LPS or live PAO1 (MOI of 10:1) for an additional 12 h. At 2 h after exposure to PAO1, 100 µg/ml gentamicin was added to the medium. f qPCR of Hmox-1 in WT MΦs treated with 2 mg/ml PP-007 for 6 h before the addition of PA-LPS for an additional 4 h. g Representative WB and densitometric analysis of HO-1 in WT MΦs pretreated with vehicle or 2 mg/ml PP-007 for 6 h and then challenged with PA-LPS (left) or PAO1 (right). WB and qPCR data are represented as the fold increase over vehicle-treated samples. mRNA levels were normalized to the 18 S level. For WB data, band intensities were normalized to the corresponding β-actin band intensity. Data are represented as the mean ± SEM of at least three biological repeats. Statistical analyses were conducted using a two-tailed unpaired Student’s t test with unequal variance: *P ≤ 0.05, **P < 0.01, and ***P < 0.001. In (b–d), *symbols indicate a statistically significant difference between PP-007-treated and vehicle-treated samples. Cropped blots are displayed, and full-length gels and blots are included in the Supplementary Methods.